Following older adults with memory decline and dementia over time
Follows people with mild cognitive impairment, Alzheimer's and vascular dementia over time.
Plain-language title generated from the registry record
Registry title: Cognitive Impairment in Ageing People
Key facts
- Where
- Guangzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people over 50 who have memory or thinking problems but do not have dementia. They are followed over time.
- Age
- Over 50 years old
- Sex
- All sexes
- Disease stage
- Not meeting the DSM-IV standard for dementia; clinical dementia rating (CDR) of 0.5
Main reasons for not taking part
- Mental retardation
- Refusing blood sampling, imaging and other examinations
- Serious organic disease, history of mental illness or physical disability (including severe aphasia) that prevents cooperation
- Contraindications to MR scanning
- Serious physical or mental illness
Read by machine on 12 November 2026.
Where in China
- Sun Yat-sen Memorial Hospital, Sun Yat-sen UniversityGuangzhou, ChinaContact: Yamet Tang, M. D., Ph. DTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Yamei Tang
- Trial code
- NCT04360200
- Record updated
- 14 September 2020
- Original description
Mild cognitive impairment (MCI) and neurocognitive disorder such as Alzheimer's disease (AD) and Vascular dementia (VaD) have become common diseases in the elderly. The burden of dementia is rising in China, with major medical, social and economic impacts. To address this important public health problem, cohort study on elderly cognitive disorders should be carry out. The methods of early prevention, early diagnosis and early treatment the cognitive disorders in elderly should be found to reduce the burden of the social and economic issue due to dementia. At present, the international corresponding guidelines have taken gene and brain imaging biomarkers as important indicators of dementia pathogenesis research, accurate diagnosis and targeted intervention. The study will construct a prospective cohort to establish database that provide not only comprehensive epidemiological data on the MCI and neurocognitive disorder in ageing people, but also complete the construction of biological samples bank and clinical diagnosis and treatment information database. Using the database, the study will identify the conversion rates from MCI to dementia and risk factors for the progression from MCI to dementia or AD. The study will also apply and develop brain structural and pathological imaging technology to support precision diagnosis of senile cognitive disorders. The study have goals to identify and validate imaging and blood/CSF biomarkers for the early detection and tracking of cognitive disorders.Read full original descriptionShow less
Cognitive Impairment in Ageing People: A Longitudinal Observational Prospective Study
Mild cognitive impairment (MCI) and neurocognitive disorder such as Alzheimer's disease (AD) and Vascular dementia (VaD) have become common diseases in the elderly. The burden of dementia is rising in China, with major medical, social and economic impacts. To address this important public health problem, cohort study on elderly cognitive disorders should be carry out. The methods of early prevention, early diagnosis and early treatment the cognitive disorders in elderly should be found to reduce the burden of the social and economic issue due to dementia. At present, the international corresponding guidelines have taken gene and brain imaging biomarkers as important indicators of dementia pathogenesis research, accurate diagnosis and targeted intervention. The study will construct a prospective cohort to establish database that provide not only comprehensive epidemiological data on the MCI and neurocognitive disorder in ageing people, but also complete the construction of biological samples bank and clinical diagnosis and treatment information database. Using the database, the study will identify the conversion rates from MCI to dementia and risk factors for the progression from MCI to dementia or AD. The study will also apply and develop brain structural and pathological imaging technology to support precision diagnosis of senile cognitive disorders. The study have goals to identify and validate imaging and blood/CSF biomarkers for the early detection and tracking of cognitive disorders.
Inclusion: Patients over 50 years old; Sign informed consent; According to DSM-IV, the diagnostic standard of dementia was not met; The clinical dementia rating (CDR) was 0.5.
Exclusion: Uncooperative subjects that have serious organic diseases, or have a history of mental illness, or have physical disability (including severe aphasia); Suffering from serious physical or mental illness; Subjects with mental retardation; Refuse to have blood sampling, imaging and other examinations; Contraindications of MR scanning.